The Drug Information Association (DIA), today announced the election of officers and directors to its Board of Directors for the 2021-2022 term. Members will assume their respective positions beginning July 1, 2021. Two new Directors and one Observer will join the Board for the upcoming term.

THE 2021-2022 DIA BOARD OF DIRECTORS

Directors

• Michael Devoy, MD, Executive Vice President for Medical Affairs and Pharmacovigilance. f Pharmaceuticals Division, Bayer AG
• Elizabeth Garner, MD, MPH, Chief Medical Officer, ObsEva
• Peter Honig, MD, MPH, Independent Scientific and Regulatory Advisor; Former Senior Vice President and Head of Worldwide Safety and Regulatory and Group Head Development China and Development Japan, Pfizer (New Board Member)
• Frank Jiang, MD, PhD, Chief Executive Officer and Chairman of the Board, CStone Pharmaceuticals (New Board Member)
• Tatyana Kosheleva, CPA, CFO, Amring Pharmaceuticals Inc
• Barbara Lopez Kunz, MS, President and Global Chief Executive, DIA
• Judith Ng-Cashin, MD, Chief Medical Officer, Eagle Pharmaceuticals
• Michael Romano, CPA, Partner, RSM US LLP
• Michael Rosenblatt, MD, Chief Medical Officer, Flagship Pioneering
• Peter Sorger, PhD, Otto Krayer Professor of Systems Pharmacology, Harvard Medical School
• Kihito Takahashi, MD, PhD, Director and Chief Operating Officer, BONAC Corporation
• Lingshi Tan, PhD, Chairman and CEO, dMed-Clinipace
• Karin Van Baelen, Head, Global Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson
• Cynthia L. Verst, PharmD, MS, President of Design and Delivery Innovation for R&D Solutions, IQVIA
• Rachel Zhang, MBA, Founder, New Path Global, LLC (Observer)

Officers

“I’m pleased to welcome Peter Honig and Frank Jiang as Directors and Rachel Zhang as Observer to the DIA Board of Directors. I’m also very happy to announce Rebecca Vermeulen as the new Chair of the Fellows of DIA, as she steps down from the DIA Board this year,” said Barbara Lopez Kunz. “We continue to thrive from the many contributions to DIA by this incredibly talented roster of thought leaders. The diverse members of our Board are dedicated to the transformative nature of science, of course, but also the need to adapt learning and knowledge-sharing in the context of global change. We lean heavily on the power of collaboration, both with our Board and with other advisors and volunteers across the globe, as we continue to deliver on DIA’s mission to accelerate the delivery of therapies to patients worldwide.”